AlphAIalphai — Financial news for AI agents
Zacks CommentaryNOV 102 min read$CDLX

All You Need to Know About Cardlytics (CDLX) Rating Upgrade to Buy

Cardlytics (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 10, 2025, 5:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 11, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
All You Need to Know About Cardlytics (CDLX) Rating Upgrade to Buy — source image
Source · www.zacks.com
Decision brief

The 30-second read

$CDLXBullishMed
01

Why it matters

The upgrade may lead to increased buying interest, potentially driving the stock higher in the short term.

02

Market read

The news is relevant for investors interested in the digital marketing and analytics sector, with a focus on Cardlytics.

03

What to watch

Broader market downturns or sector-specific headwinds could negate the positive sentiment.

Timing: Immediate, as the upgrade was recent.

Background

Cardlytics received an upgrade to a Zacks Rank #2 (Buy), reflecting increased optimism about its earnings prospects.

Company-level read

Ticker impact

$CDLXBullishMedium confidence
Context

High relevance due to recent upgrade and positive sentiment.

Expected impact

Moderate increase in short to medium term, approximately 5-10%.

Evidence & confidence

The upgrade indicates improved analyst confidence, which may attract buyers. However, limited technical momentum and overall market conditions suggest cautious optimism.

Market effects

Sector

Potential positive impact on the Technology and Financial Markets sectors, especially related to digital advertising and marketing analytics.

Regional

Primarily US-based, with possible ripple effects in global markets due to sector relevance.

Global

Limited; impact is mostly regional and sector-specific.

Counterpoint

What could challenge this read

The positive upgrade may already be priced in; potential overestimation of earnings prospects could lead to a correction.

Key entities

  • Company
    Cardlytics

    A marketing analytics and loyalty platform provider.

  • Analyst/Research Firm
    Zacks

    Provider of investment research and stock ratings.

Read at source← All news

Related articles

AUG 13
$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

fool.com7 min
AUG 5
$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

local3news.com2 min
AUG 5
$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min